IL-17 and IL-23 Biologics for Plaque Psoriasis: Key Comparisons for 2025

Executive Brief

News Report

The News: New oral options for plaque psoriasis are emerging as effective alternatives to traditional biologics.
Clinical Win: Clinicians can now offer patients more convenient treatment options with icotrokinra.
Target Specialty: Dermatology

Key Data at a Glance

PASI 75 Response Rate: 65% with icotrokinra
Enrollment: 1,200 adults
Primary Endpoint: PASI 75 at week 16

Recent advancements in biologics targeting interleukin-17 (IL-17) and interleukin-23 (IL-23) have transformed the management of moderate-to-severe plaque psoriasis. With new oral options like icotrokinra emerging, healthcare professionals must stay updated on the comparative efficacy and safety of these treatments. This report highlights the latest findings and their implications for clinical practice as of 2025.

Clinical Context

Plaque psoriasis is a chronic, immune-mediated skin condition characterized by red, scaly patches that can significantly impact patients' quality of life. The pathogenesis of psoriasis is closely linked to the overactivity of the immune system, particularly involving cytokines such as IL-17 and IL-23. Traditional treatments, including topical therapies and systemic agents, often fail to provide adequate relief for patients with moderate-to-severe disease. Biologics targeting specific pathways have emerged as effective alternatives, offering improved efficacy and safety profiles. IL-17 inhibitors like secukinumab and ixekizumab, as well as IL-23 inhibitors such as risankizumab and ustekinumab, have shown substantial efficacy in clinical trials. Furthermore, the introduction of oral agents like icotrokinra, which selectively targets the IL-23 receptor, represents a significant advancement in treatment options, potentially improving patient adherence and outcomes.

Key Findings

The icotrokinra trial demonstrated that this oral IL-23 receptor antagonist significantly reduced psoriasis severity compared to placebo, with a notable efficacy profile reported in adults with moderate-to-severe plaque psoriasis [9].

The trial enrolled 1,200 adults with moderate-to-severe plaque psoriasis, assessing the efficacy and safety of icotrokinra against placebo and deucravacitinib [9].

Event rates: 65% of patients treated with icotrokinra achieved a PASI 75 response compared to 30% in the placebo group [9].

The primary endpoint was the proportion of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) at week 16 [9].

What This Means for Clinical Practice

The emergence of icotrokinra as a viable oral option for plaque psoriasis offers clinicians a new tool to manage this challenging condition. With its favorable safety profile and the convenience of oral administration, icotrokinra may enhance patient adherence to treatment regimens. Clinicians should consider the individual patient's disease severity, prior treatment responses, and preferences when selecting an appropriate therapy. As more data become available, understanding the long-term implications of these treatments on patient outcomes will be crucial in optimizing care.

In addition, the comparative effectiveness of IL-17 and IL-23 inhibitors continues to evolve, necessitating ongoing education and adjustment in treatment strategies. Clinicians must stay informed about the latest clinical trial results and guideline updates to ensure that they are providing the most effective and personalized care for their patients with plaque psoriasis.

Clinical Perspective

Workflow: The introduction of oral therapies like icotrokinra allows for more flexible treatment plans and improved patient adherence.

Economics: Oral options may reduce overall treatment costs by minimizing the need for frequent clinic visits associated with injectable biologics.

Patient Outcomes: Improved treatment adherence can lead to better management of psoriasis and enhanced quality of life for patients.

Dr. Divya Agarwal, Dermatology

IL-17 and IL-23 Biologics for Plaque Psoriasis: Key Comparisons for 2025

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Related Articles

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: BE VIVID Trial Results

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% Skin Clearance in BE VIVID Trial

Verified HCP Portal

Related Articles

NEJM — Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

NEJM — Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

NEJM — Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

NEJM — Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response

The Lancet — Icotrokinra in psoriasis: IL-23 receptor antagonism via oral administration

The Lancet — Once-daily oral icotrokinra versus placebo and once-daily deucravacitinib